December 13, 2010
The pharmaceutical and life sciences industries have been making considerable moves to the cloud, particularly with genomic sequencing applications and clinical trial management. While there are a number of compliance-related issues that have been addressed (and a host of others that still require more robust solutions), big pharma has been taking noticeable, albeit tentative steps to the cloud.
This week at Pharmtech, Julian Upton asked Arun Kumar, Vice President and Head of the Global Life Sciences Business Unit at Infosys, an IT, business and consulting firm, about how the cloud is shaping the pharmaceutical industry.
The impact of cloud computing for the industry is still in its infancy, but is most prevalent in areas of research, development and healthcare information exchange. He states, “the explosion of data from next generation sequencing, growing importance of biologics in the research process, and importance of public-private partnerships (PPPs) to come up with new discoveries is making cloud-based computing an increasingly important aspect of R&D.”
Kumar also noted while there are some genetic sequencing and biomarker data and applications in both public and private clouds, “there is still a need for more integrated data sharing across research, development, manufacturing and sales functions to improve trials, increase time to market for drugs, and utlize feedback faster.”
For pharma, like other industries, the main driver behind cloud adoption lies in the reduced expense of maintaining in-house infrastructure. In short, it is a business advantage, even though Kumar hopes that as wider adoption continues, there will be a “greater focus on aspects related to security, privacy, data protection and IP management.”
This is a common reason, particularly in the enterprise setting, for a move to the cloud. Interestingly, this is one segment of the cloud user base that has strict compliance mandates to adhere to. The risk and expense of compliance is clearly seen as worth it for some of the early adopters of cloud in life sciences and pharma and if Kumar is correct, more are likely to climb on board in 2011.
Full story at PharmTech
Frank Ding, engineering analysis & technical computing manager at Simpson Strong-Tie, discussed the advantages of utilizing the cloud for occasional scientific computing, identified the obstacles to doing so, and proposed workarounds to some of those obstacles.
The private industry least likely to adopt public cloud services for data storage are financial institutions. Holding the most sensitive and heavily-regulated of data types, personal financial information, banks and similar institutions are mostly moving towards private cloud services – and doing so at great cost.
In this week's hand-picked assortment, researchers explore the path to more energy-efficient cloud datacenters, investigate new frameworks and runtime environments that are compatible with Windows Azure, and design a uniﬁed programming model for diverse data-intensive cloud computing paradigms.
05/10/2013 | Cleversafe, Cray, DDN, NetApp, & Panasas | From Wall Street to Hollywood, drug discovery to homeland security, companies and organizations of all sizes and stripes are coming face to face with the challenges – and opportunities – afforded by Big Data. Before anyone can utilize these extraordinary data repositories, however, they must first harness and manage their data stores, and do so utilizing technologies that underscore affordability, security, and scalability.
04/02/2012 | AMD | Developers today are just beginning to explore the potential of heterogeneous computing, but the potential for this new paradigm is huge. This brief article reviews how the technology might impact a range of application development areas, including client experiences and cloud-based data management. As platforms like OpenCL continue to evolve, the benefits of heterogeneous computing will become even more accessible. Use this quick article to jump-start your own thinking on heterogeneous computing.